Aeras and Crucell announce Phase II clinical trial start in Kenya
Wednesday, September 22, 2010 - 03:07
in Health & Medicine
Dutch biopharmaceutical company Crucell N.V. and the Aeras Global TB Vaccine Foundation today announced the start of a Phase II clinical trial in infants of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35.